The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorZhang, Wen-
Autor(es): dc.creatorZhao, Yan-
Autor(es): dc.creatorZhang, Fengchun-
Autor(es): dc.creatorWang, Qian-
Autor(es): dc.creatorLi, Taisheng-
Autor(es): dc.creatorLiu, Zhengyin-
Autor(es): dc.creatorWang, Jinglan-
Autor(es): dc.creatorQin, Yan-
Autor(es): dc.creatorZhang, Xuan-
Autor(es): dc.creatorYan, Xiaowei-
Autor(es): dc.creatorZeng, Xiaofeng-
Autor(es): dc.creatorZhang, Shuyang-
Data de aceite: dc.date.accessioned2026-02-09T11:56:43Z-
Data de disponibilização: dc.date.available2026-02-09T11:56:43Z-
Data de envio: dc.date.issued2020-04-01-
Data de envio: dc.date.issued2020-04-01-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/39647-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1521661620301984#!-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1150925-
Descrição: dc.descriptionThe pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceClinical Immunology-
Palavras-chave: dc.subjectCoronavirus-
Palavras-chave: dc.subjectCytokine storm-
Palavras-chave: dc.subjectAnti-inflammation treatment-
Palavras-chave: dc.subjectSevere acute respiratory infection-
Palavras-chave: dc.subjectTratamento anti-inflamação-
Título: dc.titleThe use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.